2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Ulf Landmesser (Lead / Corresponding author), M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J. F. Belch, Jan Borén, Michel Farnier, Brian A. Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Luscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto PintoLale Tokgozoglu, Jeroen J. Bax, Alberico L. Catapano

Research output: Contribution to journalComment/debate

110 Citations (Scopus)
106 Downloads (Pure)

Abstract

The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents. This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.
Original languageEnglish
Pages (from-to)1131-1143
Number of pages13
JournalEuropean Heart Journal
Volume39
Issue number14
Early online date16 Oct 2017
DOIs
Publication statusPublished - 7 Apr 2018

Keywords

  • atherosclerosis

Fingerprint Dive into the research topics of '2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia'. Together they form a unique fingerprint.

  • Research Output

    • 110 Citations
    • 1 Article

    Corrigendum to: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [Eur Heart J (2017)

    Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L., Pinto, F. & 3 others, Tokgozoglu, L., Bax, J. J. & Catapano, A. L., 24 Nov 2017, In : European Heart Journal. p. 1-1 1 p., ehx648.

    Research output: Contribution to journalArticle

    Cite this

    Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., Grobbee, D. E., Hovingh, G. K., Luscher, T. F., Piepoli, M. F., Ray, K. K., Stroes, E. S., Wiklund, O., Windecker, S., Zamorano, J. L., ... Catapano, A. L. (2018). 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal, 39(14), 1131-1143. https://doi.org/10.1093/eurheartj/ehx549